The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells

The anti-apoptotic proteins Bcl-X(L) and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for...

Descripción completa

Detalles Bibliográficos
Autores principales: Baev, Denis V., Krawczyk, Janusz, O׳Dwyer, Michael, Szegezdi, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216386/
https://www.ncbi.nlm.nih.gov/pubmed/25379408
http://dx.doi.org/10.1016/j.lrr.2014.06.001
_version_ 1782342254204026880
author Baev, Denis V.
Krawczyk, Janusz
O׳Dwyer, Michael
Szegezdi, Eva
author_facet Baev, Denis V.
Krawczyk, Janusz
O׳Dwyer, Michael
Szegezdi, Eva
author_sort Baev, Denis V.
collection PubMed
description The anti-apoptotic proteins Bcl-X(L) and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all patient samples tested. The efficacy of ABT-737 against AML blasts and the primitive CD34(+)/CD38(−) population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics promising candidates for future AML treatment regimens.
format Online
Article
Text
id pubmed-4216386
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-42163862014-11-06 The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells Baev, Denis V. Krawczyk, Janusz O׳Dwyer, Michael Szegezdi, Eva Leuk Res Rep Case Report The anti-apoptotic proteins Bcl-X(L) and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all patient samples tested. The efficacy of ABT-737 against AML blasts and the primitive CD34(+)/CD38(−) population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics promising candidates for future AML treatment regimens. Elsevier 2014-09-01 /pmc/articles/PMC4216386/ /pubmed/25379408 http://dx.doi.org/10.1016/j.lrr.2014.06.001 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Case Report
Baev, Denis V.
Krawczyk, Janusz
O׳Dwyer, Michael
Szegezdi, Eva
The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
title The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
title_full The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
title_fullStr The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
title_full_unstemmed The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
title_short The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
title_sort bh3-mimetic abt-737 effectively kills acute myeloid leukemia initiating cells
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216386/
https://www.ncbi.nlm.nih.gov/pubmed/25379408
http://dx.doi.org/10.1016/j.lrr.2014.06.001
work_keys_str_mv AT baevdenisv thebh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT krawczykjanusz thebh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT odwyermichael thebh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT szegezdieva thebh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT baevdenisv bh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT krawczykjanusz bh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT odwyermichael bh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells
AT szegezdieva bh3mimeticabt737effectivelykillsacutemyeloidleukemiainitiatingcells

Ejemplares similares